Ziprasidone: An overview of efficacy and tolerability in the treatment of patients with an acute exacerbation of schizophrenia or schizoaffective disorder

被引：0
|
作者：
Keck, PE
Harrigan, EP
Reeves, KR
机构：
[1] UNIV CINCINNATI,COLL MED,DEPT PSYCHIAT,CINCINNATI,OH 45267
[2] PFIZER INC,PFIZER CENT RES,DEPT CLIN RES,GROTON,CT 06340
来源：
PSYCHOPHARMACOLOGY BULLETIN | 1997年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [21] Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder
    Citrome, Leslie
    Yang, Ruoyong
    Harnett, James
    Glue, Paul
    Karayal, Onur
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 285S - 285S
  • [22] Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder
    Karayal, O.
    Citrome, L.
    Yang, R.
    Harnett, J.
    Glue, P.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 160 - 160
  • [23] The efficacy of ziprasidone in schizoaffective disorder: Case report
    Dan, I
    Simu, M
    EUROPEAN PSYCHIATRY, 2004, 19 : 175S - 175S
  • [24] Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo controlled trial
    Keck, P
    Buffenstein, A
    Ferguson, J
    Feighner, J
    Jaffe, W
    Harrigan, EP
    Morrissey, MR
    PSYCHOPHARMACOLOGY, 1998, 140 (02) : 173 - 184
  • [25] Ziprasidone - A review of its use in schizophrenia and schizoaffective disorder
    Gunasekara, NS
    Spencer, CM
    Keating, GM
    DRUGS, 2002, 62 (08) : 1217 - 1251
  • [26] Ziprasidone - A review of its use in schizophrenia and schizoaffective disorder
    Harrison, Tracy Swainston
    Scott, Lesley J.
    CNS DRUGS, 2006, 20 (12) : 1027 - 1052
  • [27] Efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder
    Kujawa, M
    Stringfellow, J
    Hardy, S
    Ali, M
    Iwamoto, T
    Lam, S
    Marcus, R
    Stock, E
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 156 - 156
  • [28] The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
    Na, Kyoungsae
    Jung, Han-Yong
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 193 - 193
  • [29] The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
    Ko, Young-Hoon
    Na, Kyoung-Sae
    Kim, Chul-Eung
    Kim, Seung-Hyun
    Jeon, Yang-Whan
    Yi, Jung-Sec
    Lee, Moon-Soo
    Kim, Shin-Gyeom
    Jeong, Hyun-Ghang
    Jung, Han-Yong
    PSYCHIATRY INVESTIGATION, 2014, 11 (04) : 459 - 466
  • [30] Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial
    P. Keck Jr
    Alan Buffenstein
    James Ferguson
    John Feighner
    William Jaffe
    Edmund P. Harrigan
    Marilyn R. Morrissey
    Psychopharmacology, 1998, 140 : 173 - 184
12345